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BACKGROUND: The Australian National Cervical Screening Program, introduced more than 20 years ago, does not record the Indige-
nous status of screening participants. This article reports the first population-based estimates of participation in cervical screening
for Indigenous and non-Indigenous Australian women. METHODS: This was a retrospective, population-based study of 1,334,795
female Queensland residents, aged 20 to 69 years, who participated in cervical screening from 2000 to 2011; 26,829 were identified
as Indigenous through linkage to hospitalization records. Participation rates were calculated as the number of women screened di-
vided by the average estimated resident population, with adjustments made for hysterectomies, for each 2-, 3-, and 5-year screening
period. Multivariate logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs), which were
adjusted for age group, place of residence, and socioeconomic disadvantage. RESULTS: In 2010-2011, the 2-year participation rate
was 55.7% (95% CI, 55.6%-55.9%) for non-Indigenous women and 33.5% (95% CI, 32.9%-34.1%) for Indigenous women; this repre-
sented a decrease from 2000-2001 (57.7% [95% CI, 57.6%-57.9%] and 35.3% [95% CI, 34.5%-36.1%], respectively). The difference
between Indigenous and non-Indigenous women was greatest for those aged 45 to 49 years. The 3- and 5-year participation rates
were higher within both groups, and the absolute differences between the 2 groups were larger. Significant interactions between the
Indigenous status and the place of residence and socioeconomic disadvantage highlight that the Indigenous/non-Indigenous differen-
tial was evident in all places of residence except for very remote areas (OR, 0.99; 95% CI, 0.95-1.02) and was greatest in the most
affluent areas (OR, 0.26; 95% CI, 0.24-0.27). CONCLUSIONS: Indigenous Australian women participate less than non-Indigenous
women, and this gap has not closed. These results provide important benchmarks for the new Australian cervical screening program
commencing in 2017, which will provide opportunities to reduce inequities for Indigenous women and address longstanding data defi-
ciencies in the collection of the Indigenous status. Cancer 2016;122:1560-9. VC 2016 The Authors. Cancer published by Wiley Periodi-
cals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution
NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.
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INTRODUCTION
The Australian National Cervical Screening Program (NCSP) includes the Pap Smear Registers (PSRs), which record all
Papanicolaou (Pap) tests performed in Australia and send reminders for overdue Pap tests to women and their primary
care providers.1 Since the introduction of the NCSP in 1991, cervical cancer incidence and mortality have been halved,1
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and they are among the lowest in the world.2 The NCSP
currently recommends 2-year Pap tests for women aged
20 to 69 years, regardless of their human papillomavirus
(HPV) vaccination status, sexual orientation, ethnicity, or
religion. The PSRs provide data for detailed national
reporting of screening participation; in 2012-2013, 58%
of eligible Australian women underwent a Pap test.1
Cervical cancer has a greater impact on Aboriginal and
Torres Strait Islander women (hereafter respectfully called
Indigenous women) than non-Indigenous women. The cer-
vical cancer incidence is approximately 2 times higher (20 vs
9 per 100,000) and the mortality rates are 4 times higher (8
vs 2 deaths per 100,000) for Indigenous women versus non-
Indigenous women.1 Indigenous women are more likely to
have advanced disease when they are diagnosed3 and lower
survival rates than non-Indigenous women (5-year survival
rate, 57.6% vs 78.3%).4
Several localized studies, mostly in remote commun-
ities or regions, have reported much lower screening partici-
pation for Indigenous women than non-Indigenous
women.5-9 Participation varied considerably and ranged
from 20% to 64% in Queensland and from 17% to 75%
in the Northern Territory (NT) for Indigenous women.5,6
Since its inception, the NCSP has been unable to report on
screening participation or other outcomes for Indigenous
women because the Indigenous status is not routinely col-
lected on pathology request and report forms (PSRs’ pri-
mary data source). Consequently, no information is
available to assess the effectiveness of different access and
service delivery models or the effectiveness of interventions
to increase participation for Indigenous women.1
We identified Indigenous women in the NCSP by
linking PSR records to hospital inpatient records, for
which the quality of the Indigenous status is known to be
reasonably high.10 For the first time, we can report on
screening participation for Indigenous women versus
non-Indigenous women for an entire state, and this
includes time trends, variation by age group, place of resi-
dence, and area-level socioeconomic status.
MATERIALS AND METHODS
Data Sources and Linkage
As previously described,11 records were extracted from the
Queensland PSR for all Pap tests and cervical biopsies per-
formed between February 8, 1999 (the date on which the
Queensland PSR commenced) and December 31, 2011,
with the following inclusion criteria: a woman aged 20 to 69
years at the time of the Pap test who was a Queensland resi-
dent and had not opted out of the PSR. The PSR extract
included the date of birth (month/year), the place of resi-
dence (suburb/postcode), test date, test type (cytology/histol-
ogy), and test result. Women were excluded if insufficient
address details meant that a Queensland statistical local area
(SLA) could not be assigned to their place of residence.
Records were extracted from the Queensland Health
Admitted Patient Data Collection (QHAPDC) for all
women who were identified as Indigenous for an inpatient
episode in a Queensland public hospital during 1995-
2011. In the most recent audit of Indigenous status data
in 2011-2012 in Queensland, 87% (95% confidence
interval [CI], 84%-91%) of people who self-reported
being Indigenous were recorded as Indigenous in hospital
records.10 The QHAPDC extract was probabilistically
matched to the PSR extract on the basis of weighted key
variables (eg, name, birth date, and place of residence)
and clerical review. Women in the PSR who were linked
to the QHAPDC extract of Indigenous women were clas-
sified as Indigenous if they were identified as Indigenous
in the majority (>50%) of their inpatient episodes.11,12
Remaining women, including those whose PSR record or
records did not link to the QHAPDC extract, were classi-
fied as non-Indigenous.
Participation
Participation rates were calculated with the NCSPmethod1
and were measured as the percentage of women in the pop-
ulation aged 20 to 69 years who had been screened at least
once within a specific time period. To calculate this, the
number of women who were recorded in the PSR with at
least 1 Pap test within a specific time period (numerator)
was divided by the average estimated resident population
(ERP) for the same time period (denominator); this was
adjusted to include only those who required cervical screen-
ing (females aged 20-69 years with an intact cervix) because
women who have undergone a hysterectomy with their cer-
vix removed do not require cervical screening. Although
the exact number of women with an intact cervix is not
known, national hysterectomy fractions (all women com-
bined) have been calculated to estimate these values.1
Because these are not available separately for Indigenous
and non-Indigenous women, the same fractions were used
for both Indigenous and non-Indigenous ERPs. When a
woman had more than 1 Pap test in the specified time pe-
riod, only her first Pap test was counted.
The 2-year participation rate was calculated for each
5-year age group (20-24, 25-29, . . ., 65-69 y) separately
for Indigenous and non-Indigenous women for each 2-
year period between 2000-2001 and 2010-2011. This
analysis was also stratified by the remoteness of residence
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and area-level disadvantage. The same method was used
for calculating participation for 3-year intervals (ie, 2000-
2002, 2003-2005, 2006-2008, and 2009-2011) and
5-year intervals (ie, 2000-2004 and 2005-2009).
Five-year participation rates were calculated with the
NCSP method, and to demonstrate how the numerator
affected the estimates, 2 alternative methods for deriving
the numerator were used: 1) counting the last Pap test
(rather than their first) of a woman in the reporting period
and 2) identifying a cohort of women who were 20 to 69
years old at the start of the 5-year period and counting
their first Pap test. The denominator in each case was the
average ERP, adjusted by hysterectomy.
Geographical Variables
Residential suburb and postcode information at the time
of each Pap test was mapped to the 2011 SLAs. If the
address information was insufficient to assign an SLA, in-
formation from the woman’s next available record was
used. At the time of each Pap test, SLAs were used to clas-
sify the place of residence as 1 of the 5 categories of the
Accessibility/Remoteness Index of Australia13 and to
determine an area-level socioeconomic disadvantage mea-
sure with the Index of Relative Socio-Economic Advant-
age and Disadvantage (IRSAD).14
Statistical Analyses
Distributions of characteristics are presented as propor-
tions for categorical variables, with chi-square tests used to
compare groups. To account for differences in age struc-
tures between Indigenous and non-Indigenous women,
we directly age-standardized the participation rates
according to the age distribution for women in the 2001
Australian ERP.15
To assess the screening history, we looked at the ex-
perience of all women aged 30 to 69 years who had under-
gone a Pap test in 2010-2011 (and likely should have
undergone screening in the previous 10 years). Using a
10-year look-back period (2000-2009), we classified their
screening history as any screening versus no previous
screening.
Logistic regression was used to examine the associa-
tion (expressed as an odds ratio [OR]) between Indige-
nous status and participation in screening. Because the
PSR is population-based, counts of nonscreened women
in the population are assumed to be the difference
between the ERP and the number of women screened.
The proportion of women who opt out of the PSR (and,
therefore, are counted as nonscreeners) has been reported
to be less than 1% in other states, but it has not been
reported for Queensland.16,17 The models for each out-
come included 5 a priori, categorical, independent varia-
bles of interest: Indigenous status, age at Pap test, 5-year
age group (reference category, 20-24 y), place of residence
(reference category, major city), and IRSAD (reference
category, most disadvantaged). Each independent variable
was also assessed for the presence of an interaction with
Indigenous status; only Indigenous status3 place of resi-
dence and Indigenous status 3 IRSAD were statistically
significant (P < .01) and were included. To report the
impact of the interactions, using the margins and lincom
commands in Stata, we calculated adjusted ORs for Indig-
enous women versus non-Indigenous women for each cat-
egory of IRSAD and place of residence. Simple linear
regression was used to graphically represent the associa-
tion of participation rates and time periods stratified by
Indigenous status.
All analyses were conducted with Stata 14.0 (Stata-
Corp, College Station, Texas). Approvals from the ethics
committees of Queensland Health (HREC/15/QCH/19-
957), the NT Department of Health and Menzies School
of Health Research (HOMER-2012-1737), and Charles
Darwin University (H12093) were obtained, with appro-
vals for data access and linkage from data custodians, the
Queensland Research Linkage Group, and the Director
General of Queensland Health.
RESULTS
After the exclusion of 1545 women with conflicting dates
of birth (2.0% Indigenous) and the exclusion of 3164
women (3.9% Indigenous) with insufficient address
details (11,072 Pap tests), the final data set contained
1,334,795 women residing in Queensland with
4,565,250 Pap tests performed during 2000-2011. Of
these women, 26,829 (2%) were identified as Indigenous
(87,372 Pap tests). Indigenous and non-Indigenous
women in the cohort were younger than women in the re-
spective ERPs (likely because of women captured at their
first Pap test), with minor differences in the place of resi-
dence for Indigenous women (Table 1).
Two-Year Participation
Age-standardized 2-year participation rates decreased
between 2000-2001 and 2010-2011 from 35.3% (95%
CI, 34.5%-36.1%) to 33.5% (95% CI, 32.9%-34.1%)
for Indigenous women and from 57.7% (95% CI,
57.6%-57.9%) to 55.7% (95% CI, 55.6%-55.9%) for
non-Indigenous women (Table 2). Two-year participa-
tion was more than 20 percentage points lower (range,
21.1-23.6) for Indigenous women versus non-Indigenous
Original Article
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women throughout the study (Fig. 1). For 2010-2011
screening rates to be equal for both groups, 8606 extra In-
digenous women would have needed to be screened.
Participation was lower for Indigenous women than
non-Indigenous women in every age group in every time pe-
riod (Fig. 2); the differential was largest for women aged 45
– 49 years. Participation was highest for non-Indigenous
women in the 45- to 49-year age group; in 2010-2011,
60.8% (95% CI, 60.4%-61.3%) of non-Indigenous
women and 33.4% (95%CI, 31.5%-35.4%) of Indigenous
women participated (a 27 percentage point difference). In
contrast, Indigenous women’s participation rate was highest
among those aged 30 to 34 years; in 2010-2011, 37.1%
(95% CI, 35.5%-38.3%) of Indigenous women and 56.5%
(95% CI, 56.1%-56.9%) of non-Indigenous women par-
ticipated (a 19.4 percentage point difference).
Over time, participation increased among Indigenous
women aged 65 to 69 years from 21.3% (vs 42.2% for non-
Indigenous women) in 2000-2001 to 32.9% (vs 47.5% for
non-Indigenous women) in 2010-2011; this makes the 14
percentage point differential in 2010-2011 the smallest
observed across all age groups and time periods. For both
TABLE 2. Age-Standardized Participation Rates
of Women Aged 20 to 69 Years Over Time by








2000–2001 35.3 (34.5–36.1) 57.7 (57.6–57.9)
2002–2003 36.3 (35.5–37.1) 57.4 (57.3–57.6)
2004–2005 35.5 (34.8–36.2) 56.5 (56.4–56.7)
2006–2007 35.1 (34.4–35.8) 57.9 (57.8–58.0)
2008–2009 34.3 (33.7–35.0) 58.0 (57.8–58.1)
2010–2011 33.5 (32.9–34.1) 55.7 (55.6–55.9)
3-y participation
2000–2002 44.0 (43.1–44.8) 69.2 (69.0–69.4)
2003–2005 44.7 (43.8–45.5) 69.9 (69.8–70.1)
2006–2008 43.2 (42.4–43.9) 69.8 (69.7–70.0)
2009–2011 41.8 (41.1–42.5) 68.3 (68.2–68.5)
5-y participation
2000–2004 51.6 (50.7–52.6) 80.6 (80.4–80.8)
2005–2009a 50.6 (49.8–51.4) 79.8 (79.6–79.9)
2007–2011a 50.1 (49.3–50.8) 79.7 (79.5–79.8)
Abbreviation: CI, confidence interval.
Rates were age-standardized with the estimated resident population for
Australia for 2001.
a Both ranges include 2007 and 2008.
TABLE 1. Demographic Characteristics of Women at Their First Recorded Papanicolaou Test in the Queens-
land Pap Smear Register and Corresponding Proportions of Women in the Estimated Resident Population,
2000–2011
Variable














20–24 y 31.6 16.8 21.7 10.8
25–29 y 17.2 14.9 14.7 10.8
30–34 y 14.1 14.4 13.6 11.1
35–39 y 11.3 13.6 12.4 11.6
40–44 y 8.6 11.6 10.8 11.6
45–49 y 6.7 9.5 8.9 11.2
50–54 y 4.4 7.5 7.1 10.4
55–59 y 3.0 5.6 5.0 9.2
60–64 y 2.1 3.8 3.5 7.6
65–69 y 1.0 2.5 2.3 5.9
IRSAD
Most disadvantaged 27.4 38.5 11.4 13.3
Quintile 2 34.6 26.9 21.8 21.8
Quintile 3 18.2 19.8 23.1 24.5
Quintile 4 15.2 10.6 25.0 23.5
Most affluent 4.6 4.2 18.8 17.0
Place of residence
Major city 25.0 29.4 62.2 63.5
Inner regional 15.9 17.3 19.3 19.9
Outer regional 39.5 31.0 16.7 14.9
Remote 7.9 7.9 1.1 0.9
Very remote 11.7 14.4 0.7 0.8
Abbreviations: ERP, estimated resident population; IRSAD, Index of Relative Socio-Economic Advantage and Disadvantage.
a Number of women by their characteristics at their first Papanicolaou test as a proportion of the total number of women by Indigenous status.
b Average number of women as a proportion divided by the average ERP from 2000 to 2011.
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groups, participation in the 20- to 24-year age group and, to
a lesser extent, the 25- to 29-year age group decreased
between 2000-2001 and 2010-2011 (Fig. 2), most notably
among Indigenous women aged 20 to 24 years.
Indigenous women participated less than non-
Indigenous women in every remoteness category and
screening period (Table 3). Outer regional areas had the
highest participation for Indigenous and non-Indigenous
women in each screening period. In 2010-2011, participa-
tion in outer regional areas was 44.0% (95% CI, 42.8%-
45.3%) for Indigenous women and 64.4% (95% CI,
64.1%-64.8%) for non-Indigenous women (Fig. 3). In the
same time period, participation in major cities was 53.3%
(95% CI, 53.1%-53.4%) among non-Indigenous women
and 26.7% (95% CI, 25.7%-27.8%) among Indigenous
women. Participation increased with increasing affluence
for both Indigenous and non-Indigenous women (Table
4). In 2010-2011, participation among women living in
the most disadvantaged areas was 25.2% (95% CI, 24.3%-
26.0%) for Indigenous women and 49.1% (95% CI,
48.8%-49.5%) for non-Indigenous women.
Longer Screening Intervals
Three-year participation was lower for Indigenous women
than non-Indigenous women by an average of 26 percent-
age points (range, 24.6-27.4), and it decreased between
2000-2002 and 2009-2011 from 44.0% (95% CI,
43.1%-44.8%) to 41.8% (95% CI, 41.1%-42.5%) for
Indigenous women and from 69.2% (95% CI, 69.0%-
69.4%) to 68.3% (95% CI, 68.2%-68.5%) for non-
Indigenous women (Table 2). Five-year participation was
lower for Indigenous women by an average of 29 percent-
age points (range, 28.2-29.4). Approximately 50% of In-
digenous women and 80% of non-Indigenous women
were screened during 2007-2011. The estimated 5-year
rate varied with the method used to estimate the numera-
tor, although the differences were similar for Indigenous
and non-Indigenous women (Table 5).
Multivariate Analysis
Associations between screening participation and the 2-
year calendar period, age group, and Indigenous status
both by place of residence and by IRSAD are shown in
Table 6. Participation was lower for women younger than
30 years and those older than 50 years, and this trend was
similar for Indigenous and non-Indigenous women.
There was evidence of a decrease in participation from
2000 to 2011: 1% (OR, 0.99; P < .001) and 2% (OR,
0.98; P< .001) per 2-year period among non-Indigenous
and Indigenous women, respectively. However, according
to the interaction between year and Indigenous status,
Figure 1. Two-year participation rates of women aged 20 to
69 years for cervical screening by Indigenous status, 2000-
2001 to 2010-2011, in Queensland, Australia.
Figure 2. Age-specific 2-year participation rates by Indigenous
status, 2000-2001 to 2010-2011, in Queensland, Australia.
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these trends were not significantly different. The signifi-
cant interaction between Indigenous status and both place
of residence and IRSAD highlighted how the Indigenous
differential varied by location. The Indigenous/non-In-
digenous differential was greatest for Indigenous women
living in the most affluent areas (OR, 0.26, 95% CI, 0.24–
0.27) and was evident for all place-of-residence categories
except for very remote areas, where the likelihood of being
screened was similar for both groups after adjustments.
Screening History
In 2010-2011, 548,549 women aged 30 to 69 years had a
Pap test (1.6% Indigenous). Of these women (both
groups), 90.7% had a history of a previous Pap test in
2000-2009. The proportions of women who had a Pap
test in 2010-2011 without a history of a Pap test in 2000-
2009 were similar for Indigenous (8.5%) and non-
Indigenous women (9.3%).
DISCUSSION
Overall participation in cervical screening has remained 20
percentage points lower for Indigenous women versus non-
Indigenous women in Queensland for more than a decade.
Furthermore, participation appears to be declining over
time. This is the first time that population-based data on
cervical screening participation have been available for In-
digenous women in Australia. Previous studies used indi-
rect estimates to report on Indigenous women’s
participation by investigating screening in Indigenous com-
munities (Indigenous population> 70%).5,6,18 In the NT,
Indigenous women’s participation was increased from
approximately 30% in 1997-1998 to 44% in 1999-2000.5
Although the cervical cancer incidence was declining before
the NT PSR commenced in 1996, it is plausible that an
increase in screening contributed to this decline.18 National
evidence suggests that cervical cancer incidence and mortal-
ity are decreasing for Indigenous women;19 along with
trends in the NT, this suggests that cervical cancer preven-
tion efforts have had some positive effects for Indigenous
women. With methods similar to those used in the NT,5
Queensland Indigenous women’s participation was esti-
mated to be 17 percentage points lower than that of non-
Indigenous women during the early years of the Queens-
land PSR.6 Since then, there has been no further informa-
tion about Indigenous women’s participation in the
program. There is also no evidence of cervical cancer inci-
dence trends among Indigenous women in Queensland.
The decline in participation rates among younger
women in our study is consistent with national reports1
and reports showing that participation is lower among
HPV-vaccinated women.20 The effect of vaccination sta-
tus on Indigenous women’s cervical screening participa-
tion is unknown.
The linkage of data sets was deemed successful,11
although it is inevitable that we did not identify all Indige-
nous women in the PSR because some true matches may
have been missed, the Indigenous status on some hospital
records may have been misclassified as non-Indigenous
(particularly in urban areas10), and some Indigenous
women in the Queensland PSR would not have had a
public hospital record during the study. As such, it is
Figure 3. Age-standardized proportions of screened women
aged 20 to 69 years by remoteness category and Indigenous
status, 2010-2011, in Queensland, Australia.









First Papanicolaou test 50.1 (49.3–50.8) 79.7 (79.5–79.8) 29.6
Last Papanicolaou test 52.3 (51.5–53.1) 81.7 (81.5–81.9) 29.4
Age of 20–69 y at beginning of 2007,
first Papanicolaou test
48.5 (47.7–49.2) 76.8 (76.6–77.0) 28.3
Abbreviation: CI, confidence interval.
Rates were age-standardized with the estimated resident population for Australia for 2001.
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likely that we underestimated the participation rates for
Indigenous women. We were unable to quantify the
extent of the underestimation for Indigenous women who
had not been to a hospital but were recorded in the PSR
or for Indigenous women who had a record in the PSR
but failed to link to their true QHAPDC record or
records.14,21 However, to account for misclassification in
the QHAPDC, the Australian Institute of Health and
Welfare (AIHW) recommends using a correction factor
of 8% for Queensland.10 Therefore, 2-year participation
for Indigenous women in Queensland could be up to a
maximum of 38% rather than 35%. The AIHW recom-
mends different correction factors by remoteness within
Queensland (1.17 in major cities and 0.97 in very remote
areas) because the accuracy of Indigenous identification
improves with increasing remoteness.10 If we applied the
correction factor of 1.17, the participation rate for Indige-
nous women in major cities in 2010-2011 could be
31.2% rather than 26.7%.10 The accuracy in recording
Indigenous status has improved over time in the
QHAPDC, so greater underestimation may have
occurred in the early periods of the study. However, using
a majority-based algorithm to determine Indigenous sta-
tus may have helped us to overcome this. We are reason-
ably confident that most Indigenous women eligible for
our study had a record in the QHAPDC. The number of
Indigenous women aged 20 to 69 years at any time
between 1995 and 2011 in the extract from the
QHAPDC used to link to the PSR in our study exceeded
the Queensland resident 2011 ERP of Indigenous women
aged 20 to 69 years at any time between June 1995 and
December 2011.11,22,23 Two percent of women in the
PSR were linked to an Indigenous identified record in the
QHAPDC. This is lower than the proportion of Indige-
nous women in the Queensland female population
(2.95% of Queensland females in the 20- to 69-year age
group24) but plausible because participation rates are not
100%.1 We found declining participation rates for
younger Indigenous women in the later years of the study,
but careful consideration is needed when one is interpret-
ing these results. Because our study was able to identify
only Indigenous women hospitalized in a public hospital
during 1995-2011, younger Indigenous women who
entered our study later may have been less likely to have
been to a hospital and, therefore, more likely to be incor-
rectly classified as non-Indigenous. Linking the PSR to
another source of data (eg, immunization records) could
possibly improve the accuracy of the Indigenous status for
younger women. Indigenous women identified in our
study cohort are possibly somewhat different from Indige-
nous women who have never been hospitalized, and these
differences may be related to their screening behavior.25
The incidence of hysterectomies may be lower among In-
digenous women than non-Indigenous women.26 How-
ever, we were unable to use different hysterectomy
fractions for Indigenous women because adequate data
were not available. A sensitivity analysis calculating partic-
ipation rates for women aged 25 to 40 years (<5% of the
population have had a hysterectomy,1 and any differential
effects should be minimal) showed little difference in the
estimates compared with those for women aged 20 to 69
years (data not shown). The Queensland PSR does not re-
cord the hysterectomy status of women in the register.
Because women who have undergone a partial hysterec-
tomy or hysterectomy not for a benign reason may still
require screening, we may have counted women in the nu-
merator who did not have an intact cervix but excluded
them from the denominator. We are unable to quantify
this and acknowledge this as a potential limitation.
Recently, Australia announced that a renewed cervi-
cal screening program (known as the Renewal) will be
implemented in 2017, and this will change the current 2-
TABLE 6. Multivariate Analysis of 2-Year Participa-
tion, 2000–2001 to 2010–2011, in Queensland
Variable Odds Ratio (95% CI)a
2-y periodb,c 0.99 (0.99–0.99)
Age groupc,d
20–24 y 0.64 (0.63–0.64)
25–29 y 0.86 (0.86–0.87)
30–39 y 1.0
40–49 y 1.03 (1.02–1.03)
50–59 y 0.92 (0.92–0.93)
60–69 y 0.65 (0.65–0.66)
IRSAD: Indigenous/non-Indigenous
Most disadvantaged 0.53 (0.53–0.54)
Quintile 2 0.54 (0.53–0.55)
Quintile 3 0.47 (0.46–0.48)
Quintile 4 0.62 (0.60–0.64)
Most affluent 0.26 (0.24–0.27)
Place of residence: Indigenous/non-Indigenous
Major cities 0.49 (0.48–0.49)
Inner regional 0.34 (0.33–0.34)
Outer regional 0.41 (0.40–0.42)
Remote 0.48 (0.46–0.50)
Very remote 0.99 (0.95–1.02)
Abbreviation: CI, confidence interval; IRSAD, Index of Relative Socio-
Economic Advantage and Disadvantage.
a The logistic regression compares women who participated in cervical
screening with the population; adjustments have been made for all other
variables in the table, and interaction terms for the Indigenous status and
IRSAD and for the Indigenous status and remoteness are included.
b The odds ratio compares one 2-year period with the next.
c There was no significant difference between Indigenous and non-
Indigenous women.
d The odds ratio compares the age group with the referent category (30–39
years).
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year screening by Pap test to 5-year primaryHPV screening
for women aged 25 to 69 years. Further reductions of 15%
to 22% in cervical cancer incidence and mortality rates in
the population are expected because of the higher sensitivity
and better negative predictive value of HPV testing.21 The
Renewal will offer self-collection of HPV samples for
underscreened and never screened women and move from
the current reminder-based screening system to a call and
recall system. The call and recall system will actively send
invitations before the rescreening due date and invite
women to start screening on their 25th birthday.
Our study findings provide an important bench-
mark for screening behavior before the implementation of
the Renewal. Our results indicate that Indigenous women
who are screened do so regularly (although not as fre-
quently as non-Indigenous women), and this may indicate
that Indigenous women who do not undergo screening
never undergo screening. Age-specific participation varied
among Indigenous and non-Indigenous women; this
included much lower screening participation among In-
digenous women in the age group in which cervical cancer
is likely to develop (mean age of diagnosis, 48.7 years27).
Declining participation among all younger women high-
lights the importance of HPV vaccination in this age
group to increase protection against the most common
oncogenic HPV types and the need to emphasize to young
women the importance of participating in cervical screen-
ing regardless of their HPV vaccination status.
Our findings indicate that participation is highest in
outer regional areas for both Indigenous and non-
Indigenous women. Participation in very remote areas is
relatively low for all women, and this signifies that access to
services is likely difficult and needs improvement. Within
major cities, participation is higher for non-Indigenous
women than Indigenous women; this indicates that locally
available services are not meeting the needs of Indigenous
women. Rates in urban areas are likely to be underesti-
mated because the identification of Indigenous women is
less accurate in urban areas than remote areas.
Importantly, our estimated 5-year participation
indicated that at least 50% of Indigenous women in
2007-2011 were screened. Although this is promising for
the Renewal (50% coverage is possible), it is concerning
that the Indigenous/non-Indigenous differential increased.
With the Renewal’s call and recall system, which includes
the opportunity to make personalized and culturally rele-
vant invitation letters and options for self-collection, it is
possible that screening coverage among Indigenous women
will be considerably improved.
We used alternative methods to calculate 5-year par-
ticipation because those previously used by the AIHW are
limited by their reliance on aggregated data.1 For exam-
ple, for the period of 2007-2011, a woman who had a Pap
test at the age of 20 years in 2010 would be included in
the numerator and the denominator, even though she
would have been in the at-risk population for only part of
the period. Our cohort-based estimates are based on
individual-level data, and including only women who
were 20 years old in 2007 ensured greater consistency
between the numerator and the denominator. Although
the method affected the actual estimates, it had a negligi-
ble impact on the Indigenous/non-Indigenous differen-
tial. A consistent and accurate method needs to be
considered before the Renewal.
After reports of indirectly estimated low participation
in Central Australia, successful efforts to increase screening
were already evident by the next reporting period, and this
gives hope that improvement is possible within Queens-
land.18 However, without ongoing surveillance, improve-
ments in the participation and evaluation of initiatives are
difficult. It is imperative that the national data collection
and register proposed by the Renewal establish mechanisms
to collect the Indigenous status and ultimately report on In-
digenous women. Furthermore, it is important that Indige-
nous women and their health care providers understand
why Indigenous identification at the point of screening is
relevant and important for improving the health of Indige-
nous people. Even once high-quality Indigenous status data
are achieved, participation rate estimates produced from
the national register may be biased if there are inconsisten-
cies between the register’s Indigenous status and the com-
parable population information from the census. As has
been done in New Zealand,28 validation by linkage of the
Australian register and the census would ensure consistent
identification of Indigenous women in both data sets.
In conclusion, in the state of Queensland, Indige-
nous women participate less often than non-Indigenous
women, and there has been no improvement in closing
this gap. Ultimately, our findings reflect the current cervi-
cal screening program but also provide critical bench-
marks before major program changes in 2017. Our
findings reinforce the critical need for the new national
register to adequately collect the Indigenous status to
monitor and evaluate screening participation and ulti-
mately reduce inequities for Indigenous women.
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